Taking on Harvard
Executive Summary
PhRMA "will fight critics like" Harvard professors (and former New England Journal of Medicine editors) Marcia Angell and Arnold Relman "who would dampen the innovation and creativity of the pharmaceutical industry," association says in letter to the Washington Post. PhRMA sent the letter in response to an editorial by Angell and Relman, "Prescription for Profit," that ran in the Post June 20
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth